peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-12. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
=== Harm assessment === Professor David Nutt, former chair of the Advisory Council on the Misuse of Drugs (ACMD) in the UK has said in 2009, "people are better off taking ecstasy or amphetamines than those [drugs] we know nothing about" and "Who knows what's in [mephedrone] when you buy it? We don't have a testing system. It could be very dangerous[;] we just don't know. These chemicals have never been put into animals, let alone humans." Les King, a former member of the ACMD, has stated mephedrone appears to be less potent than amphetamine and ecstasy, but that any benefit associated with this could be negated by users taking larger amounts. He also told the BBC, "all we can say is [mephedrone] is probably as harmful as ecstasy and amphetamines and wait until we have some better scientific evidence to support that."
Amazon services include its digital assistant Alexa, Amazon Music, and Prime Video for music and videos respectively, the Amazon Appstore for Android apps. Audible provides audiobooks for purchase and listening. RXPass is a US prescription drug delivery service. US Amazon Prime members can pay a $5 monthly fee for access to 60 medications. Beneficiaries of government healthcare programs such as Medicare and Medicaid are not eligible. Amazon Live is an e-commerce live-streaming service. The service allows promoters to stream live videos promoting or sponsoring products. Promoters (mainly celebrities or Internet influencers) can add tags to add context. Other users can watch and send messages to a global chat for any stream. In 2023 roughly a billion total viewers watched streams in the US and India. The platform is integrated into Amazon Freevee and Amazon Prime Video.
237U is also produced via an (n,2n) reaction with 238U. This only happens with very energetic neutrons. 237Np is the product of alpha decay of 241Am, which is produced through neutron irradiation of uranium-238. Heavier isotopes of neptunium decay quickly, and lighter isotopes of neptunium cannot be produced by neutron capture, so chemical separation of neptunium from cooled spent nuclear fuel gives nearly pure 237Np. The short-lived heavier isotopes 238Np and 239Np, useful as radioactive tracers, are produced through neutron irradiation of 237Np and 238U respectively, while the longer-lived lighter isotopes 235Np and 236Np are produced through irradiation of 235U with protons and deuterons in a cyclotron. Artificial 237Np metal is usually isolated through a reaction of 237NpF3 with liquid barium or lithium at around 1200 °C and is most often extracted from spent nuclear fuel rods in kilogram amounts as a by-product in plutonium production.
Sources: en.wikipedia.org
There is a slightly elevated expression level of FGFR1OP2 in pulmonary sarcoidosis, suggesting FGFR1OP2 operates in part of the wound healing pathway. FGFR1OP2 is strongly upregulated when compared to the control in an increased immune response triggered by the VAF347 ligand. FGFR1OP2 is upregulated in the monocyte derived dendritic cell response to the VAF347 ligand. VAF347 activates the aryl hydrocarbon receptor and acts on monocytes and naive CD4+ Th cells to promote development of IL-22 secreting Th cells. Langerhans cells show decreased expression of FGFR1OP2 with the null aryl hydrocarbon receptor (ligand is VAF347) in Mus musculus. The gene is also highly expressed compared to control samples in monocytopenia. It is expressed in cases of leukemia; it may have a linkage to the disease. FGFR1OP2 shows low expression levels in septic splenocytes in Mus musculus. FGFR1OP2 is expressed in fetal reticulocytes but not adult reticulocytes, suggesting it may play a role in the development of red blood cells.
Limosilactobacillus fermentum is a Gram-positive species in the heterofermentative genus Limosilactobacillus. It is associated with active dental caries lesions. It is also commonly found in fermenting animal and plant material including sourdough and cocoa fermentation. Some strains of lactobacilli formerly mistakenly classified as L. fermentum (such as RC-14) have since been reclassified as Limosilactobacillus reuteri.
3D Realms was eventually acquired in part by Interceptor Entertainment, and in 2014, Interceptor announced plans to make a new Duke Nukem game, Duke Nukem: Mass Destruction. Gearbox filed suit against 3D Realms and Interceptor based on the fact that Gearbox now owned the rights to the Duke Nukem franchise. The case was settled out of court in August 2015, with 3D Realms and Interceptor acknowledging that Gearbox has full rights to the Duke Nukem series. Following the settlement, Gearbox released Duke Nukem 3D: 20th Anniversary Edition World Tour in September 2016. The game included new levels developed in conjunction with some of the original developers, re-recorded lines by original Duke voice actor Jon St. John, and new music from original composer Lee Jackson. It was released on October 11, 2016.
Second messengers are intracellular signaling molecules released by the target cell in response to exposure to extracellular signaling molecules—the first messengers. (Intercellular signals, a non-local form of cell signaling, encompassing both first messengers and second messengers, are classified as autocrine, juxtacrine, paracrine, and endocrine signaling depending on the range of the signal.) Second messengers trigger physiological changes at cellular level such as proliferation, differentiation, migration, survival, apoptosis and depolarization. They are one of the triggers of intracellular signal transduction cascades. Examples of second messenger molecules include cyclic AMP, cyclic GMP, inositol triphosphate, diacylglycerol, and calcium. First messengers are extracellular factors, often hormones or neurotransmitters, such as epinephrine, growth hormone, and serotonin. Because peptide hormones and neurotransmitters typically are biochemically hydrophilic molecules, these first messengers may not physically cross the phospholipid bilayer to initiate changes within the cell directly—unlike steroid hormones, which usually do. This functional limitation requires the cell to have signal transduction mechanisms to transduce first messenger into second messengers, so that the extracellular signal may be propagated intracellularly. An important feature of the second messenger signaling system is that second messengers may be coupled downstream to multi-cyclic kinase cascades to greatly amplify the strength of the original first messenger signal.
Sources: en.wikipedia.org
Isoleucine (symbol Ile or I) is an α-amino acid that is used in the biosynthesis of proteins. It contains an α-amino group (which is in the protonated −NH+3 form under biological conditions), an α-carboxylic acid group (which is in the deprotonated −COO− form under biological conditions), and a hydrocarbon side chain with a branch (a central carbon atom bound to three other carbon atoms). It is classified as a non-polar, uncharged (at physiological pH), branched-chain, aliphatic amino acid. It is essential in humans, meaning the body cannot synthesize it. Essential amino acids are necessary in the human diet. In plants isoleucine can be synthesized from threonine and methionine. In plants and bacteria, isoleucine is synthesized from a pyruvate employing leucine biosynthesis enzymes. It is encoded by the codons AUU, AUC, and AUA.
The 2026 FIFA World Cup was the 23rd FIFA World Cup, the quadrennial international men's soccer championship contested by the national teams of the member associations of FIFA. The tournament began on June 11, 2026, and concluded on July 19 with Spain winning the championship for the second time. It was jointly hosted by 16 cities—11 in the United States, 3 in Mexico, and 2 in Canada. The tournament was the first FIFA World Cup to be hosted by three countries and the first to include 48 teams, an expansion from the previous 32-team format. The 2026 tournament was the second World Cup to be hosted by multiple nations, after the 2002 edition. Mexico became the first country to host the World Cup three times, having hosted the 1970 and 1986 tournaments. The United States previously hosted the World Cup in 1994, while it was Canada's first time hosting the tournament. The event returned to its traditional June–July schedule after the 2022 World Cup in Qatar, which was uniquely held in November and December to avoid Qatar's extreme summer heat. Canada, Mexico, and the United States qualified automatically as hosts, while Cape Verde, Curaçao, Jordan, and Uzbekistan made their World Cup debuts. For the first time in the tournament's history, the top four teams from the FIFA Men's World Ranking at the time of the contest (Argentina, Spain, France, and England) advanced to the semifinals. Spain won the final against defending champion Argentina 1–0 after extra time, winning its second title and first since 2010.
The two main areas of research were the action of proteolytic enzymes and the chemical (as opposed to biological) synthesis of peptides (the substrates used to explore the enzymatic reactions). Members of Fruton's lab studied cathepsin C and several other peptidases, as well as proteinases that catalyzed transpeptidation, which was thought (and ultimately confirmed) to be part of the biosynthesis of proteins. Rather than leading a team effort focused on a small number of high-priority problems, Fruton allowed members of his laboratory to choose their own problems (usually within the broad bounds of protein synthesis and proteinases). Ph.D. students and postdoctoral researchers who worked in Fruton's lab include: Mary Ellen Jones, Melvin Fried, Hannelore Würz, Peter Heinrich, Karen Nilsson, Bob Metrione, Yoshihiro Okuda, George Taborsky, Christine Zioudrou, Maxine Singer, Louis Cohen, Frederick Newth, John Thanassi, Charles Drey, Derek George Smyth, Atsuo Nagamatsu, and Milton Winitz. A number of prominent biochemists from outside Yale also spent time in Fruton's biochemistry department during his tenure as chair, including: Harry Kroll, Rosabelle McManus, John Clark Lewis, Herbert Gutfreund, Max Gruber, Frank Hird, Vernon Ingram, Hans Kornberg, Dimitrios Theodoropoulos, and Hans Tuppy. In 1953, Fruton and Simmonds completed the textbook General Biochemistry, which became one of the most influential textbooks for a generation of biochemistry students. They produced a second edition in 1958.
The Environmental Investigation Agency in 2016 estimated that 34 species of fish were being traded on the wider Chinese fish maw market. Sciaenidae (croakers/drums) are typically the most valued, due to their similarity to the historically prized and critically endangered Chinese bahaba. Other targeted fishes include eels, stonefishes, lates perch, groupers, threadfins and sturgeon.
==== European football and further loans ==== For the first half of Tottenham's 2011–12 season, Townsend was a regular in their Europa League campaign, making six appearances in the competition. He scored his second goal for the club in their final match in the competition, against Shamrock Rovers on 15 December 2011, with a curled shot from outside the box. On 23 December, he signed a contract extension, making him a Tottenham player until the end of the 2016 season. With only one other appearance for Tottenham, in the League Cup, on 1 January 2012, Townsend joined Championship club Leeds United on loan until the end of the season, but with his agent claiming he was unhappy at the club, he switched the loan to their Championship rivals Birmingham City in February. For Leeds, he made seven appearances, including what he described as "a dream debut", and scored once. For Birmingham, he made fifteen league appearances and one in the second leg of their unsuccessful promotion play-off semi-final against Blackpool.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.